BSLN (BSLN) News
Follow BSLN (BSLN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Basilea to Receive $37.5 Million Milestone Payment on Cresemba Sales
Strong Cresemba sales in Europe trigger a USD 37.5 million milestone payment to Basilea.
EQUITY | Nov 03, 2026, 06:15 AM UTC
M
Basilea Raises FY26 Income Guidance to CHF 250M, Lifts 2030 Cash Target
Basilea raised FY26 guidance for Cresemba- and Zevtera-related income to CHF 250M, 19% above its prior guidance, and increased its cumulative cash flow target through 2030 to CHF 650M. The company also outlined streamlin
EARNINGS | Oct 27, 2026, 06:04 AM UTC
L
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
Allschwil, Switzerland, September 14, 2026Basilea Pharmaceutica Ltd, Allschwil SIX:BSLN, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections
NEWS | Sep 14, 2026, 05:21 AM UTC